8-KMaterial AgreementsFinancial EventsExhibits & Filings

AMGEN INC 8-K Report, Material Agreement (May 30, 2007)

Filed May 30, 2007For Securities:AMGN

Summary

Amgen Inc. (AMGN) announced on May 29, 2007, a significant financing transaction involving the issuance of $4.8 billion in aggregate principal amount of senior notes. This includes $2.0 billion in Senior Floating Rate Notes, $1.1 billion in 5.85% Senior Notes due 2017, and $900.0 million in 6.375% Senior Notes due 2037. The net proceeds from this debt offering were approximately $3.98 billion, which were raised through a private placement to qualified institutional buyers under Rule 144A and offshore investors under Regulation S, with no registration under the Securities Act of 1933. In addition to the debt issuance, Amgen also entered into an accelerated share repurchase agreement to buy back approximately 53.3 million shares of its common stock at an initial price of $59.96 per share. The company is using a significant portion of its capital for debt financing and substantial share repurchases, indicating a strategic move to manage its capital structure and return value to shareholders. The specifics of the notes, including interest rates, maturity dates, and covenants, are detailed in the filing.

Key Highlights

  • 1Amgen issued $4.8 billion in aggregate principal amount of senior notes across three tranches: Senior Floating Rate Notes ($2.0 billion), 5.85% Senior Notes due 2017 ($1.1 billion), and 6.375% Senior Notes due 2037 ($900.0 million).
  • 2Net proceeds from the debt offering were approximately $3.98 billion.
  • 3The notes were issued through a private placement, not registered under the Securities Act of 1933, targeting qualified institutional buyers and offshore investors.
  • 4Amgen entered into an accelerated share repurchase program to buy back approximately 53.3 million shares of common stock.
  • 5The initial price for the share repurchase was $59.96 per share, with potential price adjustments expected by July 31, 2007.
  • 6The debt issuance and share repurchase indicate a significant capital management strategy by Amgen.
  • 7The notes rank equally with other senior unsecured indebtedness of Amgen.

Frequently Asked Questions